When was Vicinitas founded?

Vicinitas was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Vicinitas located?

Vicinitas is headquartered in San Francisco, United States.

How many employees does Vicinitas have?

As of Apr 30, 2026, the latest employee count at Vicinitas is 4.

Is Vicinitas a funded company?

Vicinitas is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jul 28, 2022.

When was the latest funding round of Vicinitas?

Vicinitas' latest funding was a $***** Series A round on Jul 28, 2022, with participation from 6 investors.

Where does Vicinitas rank among its competitors?

Vicinitas ranks 1315th amongst 2426 active competitors, of which 844 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Vicinitas?

Vicinitas' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Vicinitas - 2026 Company Profile, Funding & Competitors

Vicinitas is a series A company based in San Francisco (United States), founded in 2022. It operates as a Developer of therapeutics for cancer and genetic disorders. Vicinitas has raised $65M in funding from Andreessen Horowitz and Deerfield. The company has 2426 active competitors, including 844 funded and 600 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Developer of therapeutics for cancer and genetic disorders. It offers targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs) that stop the degradation of specific proteins to restore their levels to treat cancer and monogenic diseases.

Website: vicinitas.com
Social

Key Metrics

Founded Year

2022

Location

San Francisco, United States

Stage

Series A

Total Funding

$65M in 1 round

Latest Funding Round

Series A, Jul 28, 2022, $*****

Investors

Andreessen Horowitz & 5 more

Ranked

1315^th among 2426 active competitors

Employee Count

4 as on Apr 30, 2026

Similar Companies

Amphista Therapeutics & 24 more

View Vicinitas' full profile

Vicinitas is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Vicinitas Therapeutics. CIN: 120652 , United States, Active	Dec 31, 2021	-	-	-

Vicinitas has raised a total funding of $65M over 1 round. Its latest funding round was a Series A round on Jul 28, 2022 for $*****. 6 investors participated in its latest round. Vicinitas has 6 institutional investors.

Here is the list of recent funding rounds of Vicinitas:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 28, 2022	5758348	Series A	5872404	9079111	1049742	5804648

Access funding benchmarks and valuations. Sign up today!

View details of Vicinitas's funding rounds and investors

Vicinitas' employee count trend

Vicinitas has 4 employees as of Apr 26. Here is Vicinitas's employee count trend over the years:

Uncover Vicinitas' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vicinitas include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Vicinitas, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
1315th	Vicinitas 2022, San Francisco (United States), Series A	Developer of therapeutics for cancer and genetic disorders	$65M	Deerfield, Google Ventures & 4 others	31/100